Androgen receptor expression in endometrial carcinoma and its correlation with clinicopathologic features

• Main Authors: Atif Ali Hashmi, Zubaida Fida Hussain, Amna Qadri, Muhammad Irfan, Sahar Ramzan, Naveen Faridi, Amir Khan, Muhammad Muzzammil Edhi
• Format: Article
• Language: English
• Published: BMC 2018-05-01
• Series: BMC Research Notes
• Subjects: Androgen receptor; Endometrial cancer; Endometrioid carcinoma; Serous carcinoma; Carcinosarcoma
• Online Access: http://link.springer.com/article/10.1186/s13104-018-3403-9

Abstract Objectives Recent evidence suggests a role of androgen receptor expression as a prognostic and therapeutic biomarker in endometrial carcinoma, therefore in the present study we aimed to evaluate the frequency of androgen expression in different subtypes of endometrial carcinoma and its association with clinic-pathologic features. Results 18/89 (20.2%) cases of endometrial carcinoma showed positive androgen receptor expression. On the other hand, low, moderate and high androgen receptor expression was noted in 7/89 (7.9%), 10/89 (11.2%) and 1/89 (1.1%) cases respectively. 15/77 (19.48%) of endometrioid cancers and 3/7 (42.28%) cases of serous carcinoma showed androgen receptor expression; while none of the cases of clear cell or carcinosarcoma revealed androgen receptor expression. No significant association of androgen receptor expression with various clinicopathologic features of endometrial carcinoma was noted. We found that a significant subset of endometrial cancers express androgen receptor especially a serous cancers; therefore we suggest that androgen receptor expression testing should be done in endometrial carcinoma.